Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$77.86 USD

77.86
1,510,107

+1.58 (2.07%)

Updated Sep 22, 2025 11:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Astrazeneca (AZN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) closed the most recent trading day at $65.18, moving +1.54% from the previous trading session.

Zacks Equity Research

AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies

by Zacks Equity Research

Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.

Zacks Equity Research

Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi

by Zacks Equity Research

J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Large Drug Stocks to Watch as Sector Picks Up in 2023

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.

Zacks Equity Research

AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study

by Zacks Equity Research

AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.

Zacks Equity Research

Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates

by Zacks Equity Research

Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.

Zacks Equity Research

Are You Looking for a High-Growth Dividend Stock?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo

by Kinjel Shah

FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.

Zacks Equity Research

The Zacks Analyst Blog Highlights ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard

by Zacks Equity Research

ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Exxon Mobil, Coca-Cola & AstraZeneca

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), The Coca-Cola Company (KO) and AstraZeneca PLC (AZN).

Zacks Equity Research

Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down

by Zacks Equity Research

Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.

Zacks Equity Research

Apellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.

Zacks Equity Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Zacks Equity Research

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases

by Zacks Equity Research

Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.

Zacks Equity Research

Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA

by Zacks Equity Research

With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2023.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO

by Kinjel Shah

AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.

Zacks Equity Research

Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

AstraZeneca (AZN) Q4 Earnings Beat, Sales Hurt by COVID Jab

by Zacks Equity Research

AstraZeneca (AZN) beats fourth-quarter estimates for earnings while missing the same for sales.

Zacks Equity Research

AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

Zacks Equity Research

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) closed the most recent trading day at $63.15, moving -0.65% from the previous trading session.

Zacks Equity Research

GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

by Zacks Equity Research

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

Zacks Equity Research

Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints

by Zacks Equity Research

Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints. Stock declines in pre-market.

Zacks Equity Research

Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints

by Zacks Equity Research

Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.

Zacks Equity Research

Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag

by Zacks Equity Research

Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.

Zacks Equity Research

Merck (MRK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.